<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193881</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2010-01975</org_study_id>
    <secondary_id>NCI-2010-01975</secondary_id>
    <secondary_id>2009-0769</secondary_id>
    <secondary_id>8508</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM62202</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>U01CA062461</secondary_id>
    <nct_id>NCT01193881</nct_id>
  </id_info>
  <brief_title>RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer</brief_title>
  <official_title>Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling&#xD;
      pathway inhibitor RO4929097 (RO4929097) and erlotinib hydrochloride when given together in&#xD;
      treating patients with non-small cell lung cancer that is stage IV or has come back.&#xD;
      RO4929097 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To define the maximum-tolerated dose (MTD) and toxicity of RO4929097 combined with&#xD;
      erlotinib (erlotinib hydrochloride) in patients with advanced non-small cell lung cancer&#xD;
      (NSCLC). (Dose escalation portion) II. To assess whether the probability of detectable tumor&#xD;
      shrinkage or response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria&#xD;
      correlates with pre-therapy immunohistochemistry (IHC) and reverse phase protein array (RPPA)&#xD;
      expression of Notch 1, 2, 3, and 4. (Dose escalation portion) III. A preliminary, exploratory&#xD;
      assessment will be performed with respect to percent tumor shrinkage and the probability of&#xD;
      response over the first 2 cycles of therapy. (Expansion cohort) IV. A preliminary,&#xD;
      exploratory assessment will be performed with respect to change in tumor immunohistochemistry&#xD;
      (IHC) scores and reverse phase protein array (RPPA) expression for Notch 1, 2, 3, and 4 over&#xD;
      the first 2 cycles of erlotinib. (Expansion cohort)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To perform a preliminary exploratory assessment of whether probability of detectable tumor&#xD;
      shrinkage/response correlates with pre RO4929097 presence in tumor of an activating epidermal&#xD;
      growth factor receptor (EGFR) mutation, the T790M EGFR mutation, met proto-oncogene (c-MET)&#xD;
      gene amplification or insulin-like growth factor 1 receptor (IGF-1R) expression or activation&#xD;
      or various Notch pathway markers. (Dose escalation portion) II. To perform a preliminary&#xD;
      exploratory assessment of whether addition of RO4929097 to erlotinib leads to tumor&#xD;
      shrinkage/response in any tumor deposits that had previously exhibited growth on erlotinib&#xD;
      alone. (Dose escalation portion) III. Conduct a preliminary exploratory assessment on the&#xD;
      expansion cohort with respect to tumor shrinkage/response of the following over the first 2&#xD;
      cycles of erlotinib and RO4929097 treatment with and without the presence of mutation,&#xD;
      amplification, and activation of markers: tumor IHC scores and RPPA expression of the Notch&#xD;
      ligand jagged 1 (Jag1), and the Notch targets hairy and enhancer of split 1 (HES1),&#xD;
      hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1); tumor IHC scores and RPPA&#xD;
      expression of putative stem cell markers cluster of differentiation (CD)24 (decreased in stem&#xD;
      cells), CD44, CD133, dehydrogenase and of the epithelial to mesenchymal transition (EMT)&#xD;
      markers E-cadherin and vimentin; detectability in tumor of EGFR T790M mutations, MET&#xD;
      amplification, and IGF-1R expression and activation; and soluble markers of angiogenesis,&#xD;
      including stromal cell-derived factor 1 alpha (SDF-1alpha), basic fibroblastic growth factor&#xD;
      (bFGF), cryptic epitope of collagen IV, interleukin (IL)-6, IL-8, vascular endothelial growth&#xD;
      factor (VEGF). (Expansion cohort) IV. Conduct a preliminary exploratory assessment of whether&#xD;
      percent tumor shrinkage/response or time to progression correlates with pre-therapy IHC and&#xD;
      RPPA expression of Notch 1, 2, 3 and 4, the above Notch pathway and stem cell markers, with&#xD;
      baseline detectability of T790M mutations and MET amplification, and with baseline IGF-1R&#xD;
      expression and activation, and with change in these markers from the initial biopsy to the&#xD;
      subsequent biopsy. (Expansion cohort) V. In tumor samples collected both during the dose&#xD;
      escalation phase and in the expansion cohort, assess if IHC and RPPA expression of Notch,&#xD;
      Notch ligand and Notch targets correlates with expression of stem cell markers.&#xD;
&#xD;
      VI. Assess if percent tumor shrinkage/response, time to progression and baseline and change&#xD;
      in IHC and RPPA expression of Notch, Notch ligand, Notch targets and stem cell markers varies&#xD;
      with: tumor Notch gene amplification as assessed by fluorescent in situ hybridization (FISH);&#xD;
      tumor IHC and RPPA expression of selected members of the Wnt and Hedgehog pathways (since&#xD;
      these could lead to stem cell properties in cells that do not express Notch); host&#xD;
      (peripheral blood mononuclear cell) polymorphisms for relevant genes in the Notch pathway;&#xD;
      tumor micro ribonucleic acid (RNA) levels.&#xD;
&#xD;
      VII. Trough levels of erlotinib and RO4929097 will be measured in plasma samples of all&#xD;
      patients on the dose-escalation portion of the study approximately 24 hours after the cycle&#xD;
      1, day 1 dose and again approximately 24 hours after the cycle 2, day 1 dose. These&#xD;
      measurements are being done to permit a preliminary exploratory assessment of whether there&#xD;
      is induction of metabolism of one or both drugs that will lead to decreased drug plasma&#xD;
      concentrations.&#xD;
&#xD;
      VIII. In the Expansion Cohort, plasma levels of erlotinib and RO4929097 will be measured&#xD;
      approximately 24 hours after the cycle 2, day 21 erlotinib dose (just prior to initiation of&#xD;
      cycle 3), and plasma levels of both agents will be measured in plasma approximately 24 hours&#xD;
      after the cycle 3, day 1 doses of both agents. These measurements are done to permit a&#xD;
      preliminary exploratory assessment of whether: plasma drug levels correlate with % tumor&#xD;
      shrinkage/response or with change in tumor biomarkers over the first 6 weeks of therapy;&#xD;
      erlotinib plasma concentrations are affected by RO4929097 administration.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-21 and&#xD;
      gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and&#xD;
      15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events assessed using NCI CTCAE version 4.0 (Dose escalation phase)</measure>
    <time_frame>Within 30 days of last drug dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose of RO4929097 and erlotinib hydrochloride defined as the highest dose tested causing dose limiting toxicity in &lt; 2/6 patients assessed using National Cancer Institute (NCI) CTCAE version 4.0 (Dose escalation phase)</measure>
    <time_frame>At least 3 weeks after day 1 of course 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of change in expression of Notch and other tumor and blood biomarkers (Expansion cohort)</measure>
    <time_frame>Baseline to 6 weeks</time_frame>
    <description>The differences before and after treatment will be assessed using a paired-t test on the log-transformed tumor sizes and a Wilcoxon signed-rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of tumor shrinkage (Expansion cohort)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Will be correlated with response and baseline expression of biomarkers. The differences before and after treatment will be assessed using a paired-t test on the log-transformed tumor sizes and a Wilcoxon signed-rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate by RECIST 1.1 (Expansion cohort)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression (Expansion cohort)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Will be correlated with baseline expression or biomarkers.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Efficacy of this combination in unselected patients and in patients with intrinsic or acquired erlotinib resistance (Dose escalation phase)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Host Notch pathway gene polymorphisms</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Correlations between Notch pathway gene polymorphisms and tumor and blood biomarkers will be assessed. Correlations between Notch pathway gene polymorphisms and tumor shrinkage/response on therapy will also be assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pre-therapy tumor expression of Notch and other tumor and blood biomarkers (Dose escalation phase)</measure>
    <time_frame>Baseline</time_frame>
    <description>Exploratory assessments of correlations of tumor shrinkage and response on the combination with pre-therapy tumor expression of Notch and other tumor and blood biomarkers will be conducted.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stem cell markers</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Correlations between Notch pathway markers and stem cell markers will be assessed.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Recurrent Non-Small Cell Lung Carcinoma</condition>
  <condition>Stage IV Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
    <other_name>Cp-358,774</other_name>
    <other_name>OSI-774</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma-Secretase Inhibitor RO4929097</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
    <other_name>RO4929097</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib, RO4929097)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dose-escalation portion:&#xD;
&#xD;
               -  Patients must have histologically or cytologically confirmed diagnosis of&#xD;
                  incurable NSCLC&#xD;
&#xD;
               -  Preference will be given to patients with NSCLC who have been treated with&#xD;
                  erlotinib, and have either responded initially and then experienced subsequent&#xD;
                  growth in one or more tumor deposits while continuing erlotinib (acquired&#xD;
                  resistance) or patients who have been treated with erlotinib and failed to&#xD;
                  demonstrate any response to it (intrinsic resistance)&#xD;
&#xD;
          -  Expansion cohort: patients must satisfy each of the following criteria:&#xD;
&#xD;
               -  Histologically or cytologically confirmed non-small cell lung cancer that is&#xD;
                  incurable (stage IV or recurrent)&#xD;
&#xD;
               -  Patients must not have received prior anti-EGFR therapy&#xD;
&#xD;
          -  Patients on both the dose escalation portion of the study and in the Expansion Cohort&#xD;
             portion must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=&#xD;
             10 mm with computed tomography (CT) scan with cuts at 2.5 or 5 mm&#xD;
&#xD;
          -  Patients on both portions of the study must have tumor amenable to core biopsy (or to&#xD;
             incisional, excisional, or punch biopsy) for research purposes; the collaborating&#xD;
             interventional radiologists will make the determination whether or not the patient has&#xD;
             a tumor amenable to biopsy and whether or not the patient is medically an appropriate&#xD;
             candidate for tumor biopsy&#xD;
&#xD;
          -  Any prior anticancer systemic therapy or radiotherapy must have been completed at&#xD;
             least 4 weeks prior to initiation of therapy on this study; (Exception: patients may&#xD;
             be entered within 2 weeks of radiotherapy if the radiotherapy was restricted to femur&#xD;
             below the trochanter, humerus or more distal limb areas)&#xD;
&#xD;
          -  Dose escalation portion:&#xD;
&#xD;
               -  Unlimited prior therapy is permitted (including prior anti-EGFR therapy), with&#xD;
                  the exception that patients who have received prior therapy with a&#xD;
                  gamma-secretase inhibitor are not eligible&#xD;
&#xD;
               -  Prior therapy is not required&#xD;
&#xD;
               -  Preference will be given to NSCLC patients who have been treated with erlotinib&#xD;
                  with evidence of acquired or intrinsic resistance to erlotinib&#xD;
&#xD;
          -  Expansion cohort:&#xD;
&#xD;
               -  Patients may have received an unlimited number of prior systemic regimens for&#xD;
                  NSCLC (as adjuvant therapy, as therapy for locally advanced disease or as therapy&#xD;
                  for advanced disease) provided they have not received prior anti-EGFR therapy&#xD;
                  (small molecule or antibody, etc) or prior gamma-secretase inhibitors&#xD;
&#xD;
               -  Prior therapy is not required&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
          -  Platelets&gt;= 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 X&#xD;
             institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 X institutional upper limit of normal&#xD;
&#xD;
          -  International normalized ratio (INR) =&lt; 1.7 X upper limit of normal (ULN) and the&#xD;
             patient must not have received aspirin or Coumadin and the patient must not have&#xD;
             received aspirin or Coumadin within the previous week or a therapeutic dose of a&#xD;
             heparin product within the previous 24 hours&#xD;
&#xD;
          -  Women of childbearing potential must use two forms of contraception (i.e., barrier&#xD;
             contraception and one other method of contraception) from at least 2 weeks prior to&#xD;
             initiation of therapy on this study, for the duration of study participation, and for&#xD;
             at least 2 months post-treatment; should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner are participating in this study and for 2 months&#xD;
             after study participation, the patient should inform the treating physician&#xD;
             immediately&#xD;
&#xD;
               -  Women of childbearing potential are required to have a negative serum pregnancy&#xD;
                  test (with a sensitivity of at least 25 mIU/mL) within 14 days prior to the first&#xD;
                  dose of RO4929097 and a negative serum or urine pregnancy test within 24 hours&#xD;
                  prior to the first dose of RO4929097; following initiation of therapy with&#xD;
                  RO4929097, a pregnancy test (serum or urine) will be administered every 3 weeks&#xD;
                  while on study; a positive urine test must be confirmed by a serum pregnancy&#xD;
                  test; prior to dispensing RO4929097, the investigator or designate must confirm&#xD;
                  and document the patient's use of two contraceptive methods, dates of negative&#xD;
                  pregnancy test, and confirm the patient's understanding of the teratogenic&#xD;
                  potential of RO4929097&#xD;
&#xD;
               -  Patients with a positive pregnancy test who are unlikely to be pregnant may be&#xD;
                  considered for entry on this trial if they are deemed to be unlikely to be&#xD;
                  pregnant by an obstetrician or gynecologist and if the study sponsor is in&#xD;
                  agreement with their study entry&#xD;
&#xD;
               -  Female patients of childbearing potential are defined as patients who do not fall&#xD;
                  into either of the categories listed above and to whom any of the following&#xD;
                  apply:&#xD;
&#xD;
                    -  Patients with regular menses&#xD;
&#xD;
                    -  Patients, after menarche with amenorrhea, irregular cycles, or using a&#xD;
                       contraceptive method that precludes withdrawal bleeding&#xD;
&#xD;
                    -  Women who have had tubal ligation&#xD;
&#xD;
               -  Female patients may be considered to NOT be of childbearing potential for the&#xD;
                  following reasons:&#xD;
&#xD;
                    -  The patient has undergone total abdominal hysterectomy with bilateral&#xD;
                       salpingo-oophorectomy or bilateral oophorectomy&#xD;
&#xD;
                    -  The patient is medically confirmed to be menopausal (no menstrual period)&#xD;
                       for 24 consecutive months&#xD;
&#xD;
          -  Men participating in the study must also use 2 methods of contraception including 1&#xD;
             barrier method&#xD;
&#xD;
          -  Breastfeeding should be discontinued if the mother is treated with RO4929097&#xD;
&#xD;
          -  Patients with asymptomatic or minimally symptomatic brain metastases will not be&#xD;
             required to undergo cranial radiation prior to being considered for this trial, and&#xD;
             are eligible provided that it is not anticipated that they will require any of the&#xD;
             following over the course of study treatment:&#xD;
&#xD;
               -  Corticosteroids for control of cerebral edema&#xD;
&#xD;
               -  Enzyme-inducing anticonvulsants&#xD;
&#xD;
               -  Radiotherapy, surgery, or other local therapy for the brain metastases&#xD;
&#xD;
          -  Able to swallow oral medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not have received other systemic therapy or radiotherapy for their cancer&#xD;
             within the previous 4 weeks prior to planned first day of therapy on this trial;&#xD;
             (Exception: patients may be entered within 2 weeks of radiotherapy if the radiotherapy&#xD;
             was restricted to distal limbs such as femur below the trochanter, humerus or more&#xD;
             distal limb areas; in addition, patients in the dose escalation portion who have&#xD;
             previously received erlotinib may start therapy on this trial as early as 1 week after&#xD;
             stopping prior erlotinib provided all other study entry criteria are met)&#xD;
&#xD;
          -  Patients on the expansion cohort may not have received prior anti-EGFR therapy (small&#xD;
             molecule tyrosine kinase inhibitor [TKI] or antibody); (Note: this in contrast to the&#xD;
             dose escalation portion of the study in which patients with prior anti-EGFR therapy&#xD;
             will be eligible)&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to RO4929097, OSI-774 or other agents used in the study&#xD;
&#xD;
          -  Patients taking medications with narrow therapeutic indices that are metabolized by&#xD;
             cytochrome P450 (CYP450), including warfarin sodium (CoumadinÂ®) are ineligible&#xD;
&#xD;
          -  Caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates,&#xD;
             inducers, and/or inhibitors; furthermore, patients who are taking concurrent&#xD;
             medications (other than erlotinib) that are strong inducers/inhibitors or substrates&#xD;
             of CYP3A4 should be switched to alternative medications; if such patients cannot be&#xD;
             switched to alternative medications, they will be ineligible to participate in this&#xD;
             study; if a patient is taking a strong CYP3A4 inhibitor/inducer other than the 2 study&#xD;
             drugs, they should be switched to an alternative drug&#xD;
&#xD;
          -  Patients with malabsorption syndrome or other condition that would interfere with&#xD;
             intestinal absorption&#xD;
&#xD;
          -  Diarrhea &gt; grade 1 despite appropriate therapy&#xD;
&#xD;
          -  Patients who are known to be serologically positive for hepatitis A, B or C are&#xD;
             ineligible&#xD;
&#xD;
          -  Patients with &gt; grade 1 (by Common Terminology Criteria for Adverse Events [CTCAE]&#xD;
             criteria) hyponatremia or hypocalcemia (based on measurement of ionized calcium)&#xD;
             despite appropriate medical management are excluded from this study, as are patients&#xD;
             with hypophosphatemia (serum phosphate below the lower limit of normal for the&#xD;
             institution), hypomagnesemia, (serum magnesium below the lower limit of normal),&#xD;
             hypokalemia, or hyperkalemia (serum potassium outside normal limits) despite&#xD;
             appropriate medical management&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection requiring systemic therapy (with antibiotics, antiviral or antifungal&#xD;
             agents), symptomatic congestive heart failure, unstable angina pectoris, angina at&#xD;
             rest, a history of torsades de pointes, potentially life-threatening cardiac&#xD;
             arrhythmias (patients are permitted to have chronic, stable atrial fibrillation,&#xD;
             premature atrial or ventricular contractions, sinus tachycardia, provided the rate is&#xD;
             controlled at &lt; 115 per minute, and sinus bradycardia, provided the rate is &gt; 50 per&#xD;
             minute), myocardial infarction within the previous 3 months, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
&#xD;
          -  Cardiovascular: baseline corrected QT interval using Fridericia's formula (QTcF) &gt; 450&#xD;
             msec (male) or QTcF &gt; 470 msec (female)&#xD;
&#xD;
          -  Patients requiring drugs that are known to cause Torsades de pointes and/or prolonged&#xD;
             corrected QT (QTc) intervals are excluded; patients requiring drugs with a possible&#xD;
             but unproven association with Torsades de pointes and/or QTc prolongation may be&#xD;
             eligible, but will require additional electrocardiogram assessments, as outlined&#xD;
&#xD;
          -  Patients who have not recovered to &lt; CTCAE grade 2 toxicities related to prior therapy&#xD;
             are not eligible to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Gibbons</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>R04929097</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

